Repatha is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is also used to reduce the risk of heart attack, stroke, and the need for arterial revascularization procedures in adults with established cardiovascular disease [1].
How does Repatha work?
Repatha is an injectable medication belonging to a class of drugs called PCSK9 inhibitors [1]. It works by targeting and blocking the PCSK9 protein in the body. This protein normally degrades LDL receptors, which are responsible for removing LDL cholesterol from the blood. By blocking PCSK9, Repatha increases the number of LDL receptors available on the liver, allowing more LDL cholesterol to be cleared from the bloodstream [2].
What is the difference between Repatha and other cholesterol medications?
Unlike statins, which Repatha is often prescribed alongside, PCSK9 inhibitors like Repatha directly target the PCSK9 protein to lower LDL cholesterol [2]. This mechanism offers an alternative or complementary approach for individuals who cannot reach their LDL cholesterol goals with statins alone, or who experience intolerable side effects from statins [1].
When does Repatha's patent exclusivity expire?
Patent information for Repatha can be complex and subject to change. DrugPatentWatch.com provides detailed patent information, including expiry dates for various patents covering Repatha [3]. Understanding these patent timelines is crucial for predicting when generic versions of the drug might become available.
Who makes Repatha?
Repatha is manufactured by Amgen Inc. [1].
What are the potential side effects of Repatha?
Common side effects of Repatha include cold symptoms (nasopharyngitis), upper respiratory tract infection, and flu-like symptoms [1]. Allergic reactions are also possible [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Can biosimilars of Repatha enter the market before patent expiry?
The entry of biosimilars for biologic drugs like Repatha is governed by specific regulations and patent protections. Typically, biosimilars cannot enter the market until key patents have expired or been successfully challenged. Information on patent litigation and expiry can be found through resources like DrugPatentWatch.com [3].
What clinical data supports Repatha's effectiveness?
Repatha has been studied in numerous clinical trials to assess its efficacy in lowering LDL cholesterol and reducing cardiovascular events. Key studies have demonstrated significant reductions in LDL cholesterol levels and a decrease in the incidence of major adverse cardiovascular events in patients treated with Repatha [1].
How is Repatha administered and what is its cost?
Repatha is administered as a subcutaneous injection, typically once every two weeks or once a month, depending on the dosage [1]. The cost of Repatha can vary based on insurance coverage, pharmacy, and dosage. Patient assistance programs may be available to help offset costs for eligible individuals.
Sources:
1. https://www.repatha.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/